EN DE
STOCK COMPARISON

Nanjing King-friend Biochemical Pharmaceutical Co vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Nanjing King-friend Biochemical Pharmaceutical Co (603707) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees Nanjing King-friend Biochemical Pharmaceutical Co as the less overvalued of the two: Nanjing King-friend Biochemical Pharmaceutical Co trades at ¥8.10 versus a fair value of ¥6.12 (-24%), while Jiangsu Hengrui Medicine Co trades at ¥54.62 versus ¥25.94 (-53%).
Nanjing King-friend Biochemical Pharmaceutical Co
603707.SHG · CNY · Health Care
-24%
upside to fair value
overvalued
Price¥8.10
Fair Value¥6.12
Quality64/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-53%
upside to fair value
overvalued
Price¥54.62
Fair Value¥25.94
Quality66/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Nanjing King-friend Biochemical Pharmaceutical CoJiangsu Hengrui Medicine Co
Valuation
20.9×P/E (TTM)43.6×
3.02×P/S (TTM)10.84×
1.76×P/B5.76×
11.2×EV/EBITDA33.0×
—PEG0.93×
1.3%Dividend yield0.4%
¥0.10Dividend per share¥0.20
Profitability
15%Net margin25%
10%Operating margin32%
9%Return on equity15%
5%Return on assets9%
Growth
5%Revenue growth (YoY)13%
2.4%Avg. growth/yr (3Y)13.9%
6.5%Avg. growth/yr (5Y)2.5%
Balance & size
0.00×Debt / equity—
$2BMarket cap$52B
healthyGrowth qualityhealthy

Even match: 6 to 6 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Nanjing King-friend Biochemical Pharmaceutical Coof which business quality 64 · market factors 35 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 46
ProfitabilityMargins and returns on capital today
39
63
Quality GrowthAre margins and returns improving?
36
41
CashflowEarnings quality: real cash, not paper profit
74
82
Fin. StrengthBalance sheet, leverage, solvency risk
77
100
InvestmentDisciplined investing over empire-building
70
27
Low VolatilityCalm price path (market factor)
85
78
MomentumPrice trend over the last 3–12 months (market factor)
17
35
52W MomentumDistance to the 52-week high (market factor)
9
29
Net IssuanceBuybacks instead of dilution
92
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Nanjing King-friend Biochemical Pharmaceutical Co

DCF Models¥9.87
Earnings-Based¥4.77
Dividend Discount¥2.38
Multiples¥6.55
Asset-Based¥2.86
Growth DCF¥8.73
Economic Profit¥3.81
Growth Earnings¥7.44

19 of 26 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.78
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥23.65
Asset-Based¥6.44
Growth DCF¥39.88
Economic Profit¥18.21
Growth Earnings¥30.99

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Nanjing King-friend Biochemical Pharmaceutical Co
Bear ¥4.59Fair Value ¥6.12Bull ¥7.65
¥8.10 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥54.62 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Nanjing King-friend Biochemical Pharmaceutical Co · Health Care

Quality score64 · Top 25%
Fair value upside-24% · above median

Jiangsu Hengrui Medicine Co · Health Care

Quality score66 · Top 25%
Fair value upside-53% · below median

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees Nanjing King-friend Biochemical Pharmaceutical Co as the less overvalued of the two: Nanjing King-friend Biochemical Pharmaceutical Co trades at ¥8.10 versus a fair value of ¥6.12 (-24%), while Jiangsu Hengrui Medicine Co trades at ¥54.62 versus ¥25.94 (-53%).

Jiangsu Hengrui Medicine Co has the higher quality score (66/100).

See the full analysis →
Nanjing King-friend Biochemical Pharmaceutical Co · Jiangsu Hengrui Medicine Co

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Nanjing King-friend Biochemical Pharmaceutical Co

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to Jiangsu Hengrui Medicine Co

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.